Tag: KDC-MN-240

  • Pimavanserin

    Selective 5-HT2A inverse agonist

    The first FDA-approved drug for Parkinson disease psychosis; a selective 5-HT2A inverse agonist with no dopamine receptor activity.

    Abstract

    Pimavanserin (1-[(4-fluorophenyl)methyl]-1-[(1-methyl-4-piperidinyl)methyl]-3-{4-[(2-methylpropoxy)]phenyl}urea; CAS 706779-91-1; molecular formula C25H34FN3O2; molecular weight 427.56) is a selective 5-HT2A inverse agonist developed at ACADIA and approved by the FDA in 2016 under the trade name Nuplazid. Distinct among antipsychotics by absence of dopamine receptor activity: D2 affinity is greater than 1000 nM, with no clinically relevant binding. Selectivity is for 5-HT2A (Ki approximately 0.087 nM) over 5-HT2C (Ki approximately 0.4 nM, approximately 5-fold selective). The compound is a high-efficacy inverse agonist (not merely an antagonist), reducing constitutive 5-HT2A signaling below baseline. The dopaminergically clean profile is uniquely suited to Parkinson disease psychosis, where conventional antipsychotics’ D2 antagonism worsens motor symptoms; pimavanserin treats hallucinations and delusions without aggravating bradykinesia or rigidity. Plasma half-life is 57 hours for parent compound, 200 hours for active metabolite. Metabolism is via CYP3A4 and CYP3A5. The compound carries an FDA black-box warning for increased mortality in elderly dementia patients (a class warning for all antipsychotics). Used as the reference selective 5-HT2A inverse agonist.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.